ATORX
vs
OMX Stockholm 30

Over the past 12 months, ATORX has underperformed OMX Stockholm 30, delivering a return of -94% compared to the OMX Stockholm 30's 5% drop.
Stocks Performance
ATORX vs OMX Stockholm 30
Performance Gap
ATORX vs OMX Stockholm 30
Performance Gap
Performance By Year
ATORX vs OMX Stockholm 30
Alligator Bioscience AB
Glance View
Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody-based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 46 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The firm operates domestically.